

## 1 **Antibody neutralization to SARS-CoV-2 and variants after one year in Wuhan**

2

3 Qianyun Liu<sup>1, 5</sup>, Qing Xiong<sup>1, 5</sup>, Fanghua Mei<sup>2, 5</sup>, Chengbao Ma<sup>1</sup>, Zhen Zhang<sup>1</sup>, Bing Hu<sup>2</sup>,  
4 Junqiang Xu<sup>2</sup>, Yongzhong Jiang<sup>2</sup>, Faxian Zhan<sup>2</sup>, Xianying Chen<sup>1</sup>, Ming Guo<sup>1</sup>, Xin Wang<sup>1</sup>,  
5 Yaohui Fang<sup>3</sup>, Shu Shen<sup>3</sup>, Yingle Liu<sup>1</sup>, Fang Liu<sup>1</sup>, Li Zhou<sup>1</sup>, Ke Xu<sup>1</sup>, Changwen Ke<sup>4</sup>, Fei  
6 Deng<sup>3</sup>, Kun Cai<sup>2</sup>✉, Huan Yan<sup>1</sup>✉, Yu Chen<sup>1</sup>✉, Ke Lan<sup>1</sup>✉

7

8 <sup>1</sup>State Key Laboratory of Virology, Institute for Vaccine Research and Modern Virology  
9 Research Center, College of Life Sciences, Wuhan University, Wuhan, China.

10 <sup>2</sup>Hubei Provincial Center for Disease Control and Prevention, Wuhan, China.

11 <sup>3</sup>National Virus Resource Center, Wuhan Institute of Virology, Chinese Academy of Sciences.

12 <sup>4</sup>Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, China.

13 <sup>5</sup>These authors contributed equally: Qianyun Liu, Qing Xiong, Fanghua Mei

14 ✉e-mail: [ckreal@163.com](mailto:ckreal@163.com); [huanyan@whu.edu.cn](mailto:huanyan@whu.edu.cn); [chenyu@whu.edu.cn](mailto:chenyu@whu.edu.cn); [klan@whu.edu.cn](mailto:klan@whu.edu.cn)

15

## 16 **Abstract**

17 Most COVID-19 patients can build effective humoral immunity against  
18 SARS-CoV-2 after recovery(1, 2). However, it remains unknown how long the  
19 protection can maintain and how efficiently it can protect people from the reinfection  
20 of the emerging SARS-CoV-2 variants. Here we evaluated the sera from 248  
21 COVID-19 convalescents around one year post-infection in Wuhan, the earliest  
22 epicenter of SARS-CoV-2. We demonstrated that the SARS-CoV-2 immunoglobulin  
23 G (IgG) maintains at a high level and potently neutralizes the infection of the original  
24 strain (WT) and the B.1.1.7 variant in most patients. However, they showed varying  
25 degrees of efficacy reduction against the other variants of concern (P.1, B.1.525, and  
26 especially B.1.351) in a patient-specific manner. Mutations in RBD including K417N,  
27 E484K, and E484Q/L452R (B.1.617) remarkably impair the neutralizing activity of  
28 the convalescents' sera. Encouragingly, we found that a small fraction of patients' sera  
29 showed broad neutralization potency to multiple variants and mutants, suggesting the

30 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**  
existence of broadly neutralizing antibodies recognizing the epitopes beyond the

31 mutation sites. Our results suggest that the SARS-CoV-2 vaccination effectiveness  
32 relies more on the timely re-administration of the epitope-updated vaccine than the  
33 durability of the neutralizing antibodies.

34

### 35 **Main**

36 The SARS-CoV-2 emerged more than a year ago rapidly swept across the world  
37 and developed into a long-lasting COVID-19 pandemic with devastating impacts(3, 4).  
38 The situation leads to the perpetual mutation of SARS-CoV-2 with numerous variants  
39 emerging around the world. In addition to the initial D614G mutation, the viral spike  
40 protein undergone antigenic drift and produced several variants of concern associated  
41 with local outbreaks, such as B.1.1.7 (United Kingdom)(5), B.1.351 (South  
42 African)(6), P.1 (Brazil, also known as B.1.1.28.1)(7), B.1.525 (Nigeria)(8) and  
43 B.1.617 (India)(9).

44 So far, due to the lack of sufficient evidence about how long the  
45 anti-SARS-CoV-2 protective immunity induced by prior infection or vaccination can  
46 maintain, the optimal interval between the vaccinations remains to be determined(10,  
47 11). Additionally, increasing evidence showing these variants of concern, especially  
48 the South African strain B.1.351(12, 13), remarkably increased resistance to the  
49 neutralizing antibodies, which largely due to the mutations in the RBD region  
50 interacting with human angiotensin-converting enzyme 2 (hACE2)(3). It is imperative  
51 to figure out the durability and cross-variant protection of SARS-CoV-2 neutralizing  
52 antibodies elicited by previous infection or vaccination based on the original strain.

53 Wuhan is the first known epicenter of the SARS-CoV-2 outbreak. Almost all  
54 patients in this city were infected by the original strain before the city reopen and the  
55 epidemic here had been well controlled thereafter before the emergence of  
56 variants(14). In this study, sera from convalescents infected around one year ago in  
57 Wuhan were collected to investigate the SARS-CoV-2 antibody durability and the  
58 cross-variant protection over time. Results from Enzyme-linked immunosorbent assay  
59 (ELISA) and pseudovirus neutralization assay demonstrated that the SARS-CoV-2  
60 RBD-specific IgG antibodies remain detectable in most patients, which potently  
61 inhibit the infection of the SARS-CoV-2 pseudovirus (WT-D614G and B.1.1.7), but  
62 to a different extent compromised to other tested variants (P.1, B.1.525 and especially  
63 B.1.351) and mutations (K417N, L452R, E484K, and E484Q/L452R). The decline of  
64 neutralizing activity was confirmed by authentic viral neutralization assays (WT,  
65 B.1.1.7 and B.1.351). Of note, we showed eight individuals developed relatively  
66 broad immunity against the tested variants, supporting the presence of broadly  
67 neutralizing epitopes. Overall, these results provided important implications for the  
68 control of the pandemic caused by the constantly emerging SARS-CoV-2 variants.

69

#### 70 **Durability and neutralizing activity**

71 To evaluate the durability and neutralizing activity of SARS-CoV-2 antibodies  
72 after infection, we collected sera and clinical records from 248 COVID-19 patients  
73 infected around one year ago (11-12 months after symptom onset) in Wuhan. Firstly, a  
74 rapid ELISA (colloidal gold) test for SARS-CoV-2-S IgM/IgG antibody was applied.

75 79 % (197/248) of the sera tested positive for anti-SARS-CoV-2 IgG, and 2.0 %  
76 (5/248) tested positive for anti-SARS-CoV-2 IgM (Table S1). Conventional ELISA  
77 assays were then conducted to determine the anti-RBD IgG level and the competitive  
78 ability of ACE2 to RBD-binding of the sera. As we set  $OD_{450}=0.31$  (the mean  
79  $OD_{450}$  value + 3 SD of uninfected people's sera) as the cut-off value, 91 % (225/248)  
80 tested positive for anti-SARS-CoV-2-RBD IgG (**Fig. 1A**). Our results also showed  
81 that the competitive ability is highly consistent with the anti-RBD IgG level (**Fig.**  
82 **1A-E**, Table S1), indicating most RBD-targeting antibodies in the patients can  
83 interfere with the interaction between ACE2 and RBD. However, the anti-RBD IgG  
84 level and the neutralizing activity of the sera showed no statistically significant  
85 difference in patients with different severity (Fig.1a-b), gender (Fig.1c-d), and age  
86 (Fig. 1e).

87 The neutralizing activities of the sera were tested with SARS-CoV-2 pseudovirus  
88 (WT-D614G) produced based on a replication-deficient VSV pseudotyping system  
89 (VSV-dG-Luc) and a BHK-21 cell line stably expressing hACE2 (BHK-21-hACE2).  
90 234 sera (94 %) showed more than 50 % neutralization when diluted at 20-fold  
91 ( $NT_{50} > 20$ ), and 195 samples (79 %) showed 50 % neutralization under 100-fold  
92 dilution ( $NT_{50} > 100$ ). No statistically significant difference was observed between  
93 pseudovirus neutralizing activity and the disease severity (Fig. 1f). These results  
94 indicate that most patients could build and maintain an effective humoral immunity  
95 against SARS-CoV-2 for at least one year.

96

## 97 **Cross-variant protection**

98       Recently, SARS-CoV-2 variants with multiple mutations in S protein have  
99 emerged in the United Kingdom (B.1.1.7), Brazil (P.1), Nigeria (B.1.525), South  
100 Africa (B.1.351), United states (B.1.427/B.1.429)(15), India (B.1.617), *etc.* We first  
101 tested the neutralizing activity of the top 180 potent sera in Fig. 1f by the  
102 pseudoviruses of four variants, with the WT-D614G as a control (Fig. 2a). When  
103 tested at 100-fold dilution, the mean neutralization efficiency of the sera against  
104 WT-D614G is 65 %. However, the efficiency reduced to 59 % for B.1.1.7, 48 % for  
105 P.1, 43 % for B.1.525, and 35 % for B.1.351 (Fig. 2b). Interestingly, we found that a  
106 small fraction of the patients showed cross-variant neutralizing activity. Accordingly,  
107 we selected eight representative sera from those patients (group 1, relatively resistant)  
108 for further verification by NT<sub>50</sub> determination, with another eight sera (group 2,  
109 relatively sensitive) for comparison. As expected, the sera in group 1 showed only a  
110 slight decrease in NT<sub>50</sub> against the tested variants compared with WT-D614G  
111 (1.26~2.57 folds), while the sera in group 2 showed much higher sensitivity  
112 (1.83~8.10 folds). The NT<sub>50</sub> data further confirmed that the B.1.351 is the top immune  
113 escape variant among the tested strains, followed by B.1.525, P.1, and B.1.1.7,  
114 respectively (Fig. 2c-d, and Extended data 1a).

115       We further tested whether the immune escape of the tested variants is mainly  
116 attributed to the reduced neutralizing activity of SARS-CoV-2 RBD-specific  
117 antibodies. Five C57BL/6 mice were immunized three times with WT SARS-CoV-2  
118 RBD human IgG-Fc recombinant protein. Seven weeks later, the mice sera were

119 collected and tested by pseudovirus neutralization assay. Similar to most of the  
120 convalescents' sera, the sera from RBD protein immunized mice were sensitive to  
121 B.1.525, P.1, and B.1.351, but not B.1.1.7, which is reasonable as B.1.1.7 only have  
122 one mutation (N501Y) in the RBD region, a mutation without prominent immune  
123 escape effect(12, 16) (Fig. 2e). These results showed that the immune escape ability  
124 of the variants can be largely attributed to the mutations in the RBD region.

125 To define the contribution of the critical mutations in RBD region to immune  
126 escape, we produced pseudovirus bearing SARS-CoV-2 S protein (D614G) with  
127 K417N, L452R, E484K, and L452R/E484Q mutations, respectively. Notably, L452R  
128 and L452R/E484Q are two critical mutations in the B.1.427/B.1.429 (The United  
129 States) and B.1.167 (India) variant, respectively. We tested the neutralizing activity of  
130 the 180 sera by these mutants with the WT-D614G as a control. As shown in Fig. 2f,  
131 when tested at 100-fold dilution, the mean neutralization efficiency of the sera against  
132 WT-D614G is 69 %. However, the efficiency reduced to 61 % for L452R, 55 % for  
133 K417N, 54 % for E484K, and 52 % for L452R/E484Q. This result indicates that the  
134 RBD mutations are responsible for the reduction of cross-variant neutralization  
135 among the variants of concern, especially mutations on E484 and K417.

136

### 137 **Verification by authentic viruses**

138 To confirm whether the neutralization results are consistent between the  
139 SARS-CoV-2 pseudovirus and the authentic virus, we first conducted the authentic  
140 SARS-CoV-2 virus (WT) neutralization assay to verify the 30 representative sera

141 showing high, medium, and low neutralizing activities in Fig. 1f, respectively. The  
142 SARS-CoV-2 nucleocapsid (N) protein immunofluorescence assay showed consistent  
143 results with the pseudovirus neutralization assay (Fig. 3a).

144 We further verified the neutralizing activity of two groups of patients in Fig. 2  
145 c-d (relatively sensitive and relatively resistant) by three authentic SARS-CoV-2  
146 strains, including the WT strain and the B.1.1.7 and B.1.351 variant strains. The sera  
147 were diluted 100-fold, pre-incubated with these viruses, and then applied to Vero E6  
148 cells for infection neutralization assay. As shown in Fig. 3b, the neutralizing activity  
149 of the sera against the B.1.1.7 strain is similar to the WT strain but with a slight  
150 decrease. As for the B.1.351 strain, the group 1 sera (relatively resistant) efficiently  
151 neutralized the infection of both the WT and the B.1.351 strains. In contrast, the group  
152 2 sera (relatively sensitive) showed a remarkable reduction of neutralizing activity  
153 against the B.1.351 strain compared with the WT strain (Fig. 3c). Again, these results  
154 are also consistent with the results from pseudovirus neutralization assays.

155

## 156 **Discussion:**

157 Previous studies show the protective immunity against seasonal coronaviruses  
158 (HCoV-NL63, HCoV-229E, HCoV-OC43 and HCoV-HKU1) may last only 6 to 12  
159 months(17), and the titer of SARS-CoV-2 antibody has been reported to decline  
160 rapidly in the first several months(10), raising the concern about the durability of  
161 SARS-CoV-2 neutralizing antibodies elicited by either previous infection or  
162 vaccination. Additionally, SARS-CoV-2 variants are constantly emerging during the

163 COVID-19 pandemic, greatly challenging the development and application of  
164 effective neutralizing antibodies and vaccines. It is imperative to investigate the  
165 durability and cross-variant protection of the anti-SARS-CoV-2 humoral immunity.  
166 To this end, we collected convalescent sera in Wuhan in consideration of the several  
167 unique advantages over the samples collected elsewhere: (1) Wuhan is the earliest  
168 reported epicenter of COVID-19 with most patients infected more than one year ago;  
169 (2) The patients were all infected by the original WT strain without the interference of  
170 potential multi-variants infection; (3) So far, most administrated vaccines globally  
171 were designed based on the sequences of the original strain from Wuhan.

172 Firstly, we report that the effective neutralizing antibodies against SARS-CoV-2  
173 could last at least one year in most COVID-19 convalescents, while no statistical  
174 significance was observed among different severity, gender, or age (Fig. 1a-e). These  
175 results indicate that most people including asymptomatic and elderly patients could  
176 build and maintain effective anti-SARS-CoV-2 humoral immunity, with a few  
177 exceptions in each group for unknown reasons (Fig. 1). We speculate this phenotype  
178 might be attributed to the individual immune difference that deserves further study.

179 Another particular concern is the cross-variant protective efficacy of the  
180 anti-SARS-CoV-2 humoral immunity. Our study provides additional evidence that  
181 most sera collected from convalescents in Wuhan, even for one year post-infection,  
182 can still efficiently neutralize the infection of B.1.1.7 variant. However, a significant  
183 decline of efficacy was observed on P.1, B.1.525, and B.1.351 (Fig. 2b). B.1.351  
184 displayed the most prominent immune escape ability among these tested variants,

185 consisting with the previous reports(12, 13, 18). Encouragingly, sera from a few  
186 individuals showed resistance to all tested variants (Fig. 2c), indicating the presence  
187 of effective and broadly neutralizing antibodies. It brings hope for the identification of  
188 ideal broad neutralization epitopes essential for the development of antibody therapy  
189 and next-generation vaccines.

190 We next sought to characterize the critical residues that contribute to the  
191 immune escape. Based on previous studies and our neutralization results from RBD  
192 vaccinated mouse sera, we focus on the four mutation sites in RBD of the tested  
193 variants in this study (Fig. 2a). N501Y is the only mutation in B.1.1.7 RBD, but this  
194 variant did not show remarkable immune escape in both our (Fig. 2e) and prior  
195 studies(19, 20). Therefore, we tested several mutations in the other three critical sites,  
196 including K417N, L452R, E484K, and L452R/E484Q. The neutralization assay  
197 demonstrated that the L452R/E484Q (two key mutations of B.1.617) showed the  
198 strongest immune escape, followed by E484K, K417N, and L452R. The mean sera  
199 neutralization efficiency (Fig. 2b and 2f) demonstrated that the critical RBD  
200 mutations play a major role in the immune escape of the variants. Importantly, the  
201 cross-variant protective sera from the group 1 convalescents can also tolerate these  
202 critical mutations (Fig. 2f).

203 We do acknowledge some limitations of our studies. First, we did not determine  
204 the NT<sub>50</sub> of all the sera because of the limitation of the sample volume, especially for  
205 those with lower neutralizing activity. Second, we did not include all the possible  
206 mutations that can appear in the B.1.617 and its sub-lineages in consideration of the

207 sequence complexity of the variants circulating in India. Thus, future studies could be  
208 done to investigate whether other mutations on spike proteins can result in a leap of  
209 the immune escape ability of B.1.617 and other variants.

210 To our knowledge, the current study provides the first direct evidence that the  
211 potent anti-SARS-CoV-2 humoral immunity can last for at least one year in most  
212 convalescents to protect them against the original virus (WT or WT-D614G), which  
213 means the annually re-administration might be a feasible vaccination strategy to  
214 maintain the anti-SARS-CoV-2 humoral immunity. However, the convalescents and  
215 the vaccinated people are gradually losing protection against the constantly emerging  
216 immune escape variants. It remains to be determined whether re-administration of the  
217 variant-based or broadly neutralizing epitope-based vaccines can achieve effective  
218 cross-variant immunity. Overall, our study suggests that the timely update of the  
219 vaccines rather than the durability of the SARS-CoV-2 humoral immunity should be  
220 more of our concern.

221

## 222 **Method**

### 223 **Sample collection**

224 Convalescent sera were collected from a cohort of individuals with prior  
225 SARS-CoV-2 infection, collected between January 19, 2021 and January 26, 2021,  
226 305 to 388 days after disease onset. And the illness severity, gender, and age range of  
227 donors were recorded. Sera from 10 healthy donors were also obtained. All blood  
228 donors provided written informed consent for participation in the study. These human

229 sera protocols were approved by the Ethics Committee of Hubei Provincial Center for  
230 Disease Control and Prevention, Wuhan, China (No. 2021-012-01). Sera of the  
231 RBD-hFc vaccinated mice (three times immunization) were collected seven weeks  
232 post the last immunization from the suborbital venous plexus. The mice sera protocols  
233 were approved by the Institutional Animal Care and Use Committee (IACUC) of  
234 Center for Animal Experiment, Wuhan University, Wuhan, China (No. WP20210007).

235

### 236 **ELISA detection of SARS-CoV-2 S protein antibodies in the sera**

237 The rapid IgG / IgM test was applied by 2019-nCoV IgG / IgM Detection Kit  
238 (Colloidal Gold-Based, Vazyme Biotech Co.,Ltd), which is based on the reactivity of  
239 IgG / IgM against SARS-CoV-2 S protein. The anti-RBD IgG level in sera was tested  
240 by SARS-CoV-2 (2019-nCoV) Spike RBD Antibody Titer Assay Kit (Sino Biological  
241 Inc), which is based on the reactivity of IgG against SARS-CoV-2 RBD. The  
242 competitive ability of ACE2 to RBD-binding of sera was tested through SARS-CoV-2  
243 Neutralizing Antibodies Test Kit (ELISA, Wuxi BioHermes Bio & Medical  
244 Technology Co., Ltd), which is based on the competition between the neutralizing  
245 antibodies in sera and ACE2 to horseradish peroxidase labeled RBD protein  
246 (HRP-RBD). These ELISA detections were applied following the manufacturer's  
247 instructions.

248

### 249 **Cell culture**

250 HEK 293T (ATCC, CRL-1168), BHK-21(ATCC, CCL-10) and VERO E6 cells

251 (ATCC, CRL-1586) were cultured in Dulbecco's medium (DMEM; Gibco)  
252 supplemented with 10 % fetal bovine serum (FBS), 2.0mM L-Glutamine, 110 mg/L  
253 sodium pyruvate, and 4.5 g/L D-glucose. BHK-21-ACE2 (clone 7) which stably  
254 expression human ACE2 was generated based on BHK-21 through lentiviral  
255 transduction and maintained with puromycin at 1 µg/ml. I1-Hybridoma (CRL-2700)  
256 secreting a monoclonal antibody targeting VSV glycoprotein was cultured in  
257 Minimum Essential Medium with Earle's salts and 2.0 mM L-Glutamine (MEM;  
258 Gibco) supplemented with 10 % FBS. All cells were cultured at 37°C in 5 % CO<sub>2</sub> with  
259 regular passage of every 2-3 days.

260

## 261 **Plasmids and protein**

262 The DNA sequences of human codon-optimized S proteins from SARS-COV-2  
263 variants (B.1.1.7, GISAID: EPI-ISL-601443; B.1.351, GISAID: EPI\_ISL\_678597; P.1,  
264 GISAID: EPI\_ISL\_906075; B.1.525, GISAID: EPI\_ISL\_1093472) and S protein  
265 mutations were commercially synthesized or generated by overlapping-PCR based  
266 mutagenesis using pCAGGS-SARS-CoV-2-S-C9 (gifted from Dr. Wenhui Li,  
267 National Institute of Biological Science, Beijing, China) as template and cloned into  
268 pCAGGS vector with C-terminal 18 aa truncation to improve VSV pseudotyping  
269 efficiency(21). The plasmid pCAGGS-SARS-CoV-2-RBD-hFc was constructed by  
270 inserting the RBD sequence (aa331-525) in to the pCAGGS vector for the expression  
271 of RBD-hFc recombinant protein in HEK 293T cells. The proteins were purified by  
272 protein A resin (GenScript) following the manufacturer's instructions.

273

#### 274 **SARS-CoV-2 pseudovirus production and titration**

275 The pseudovirus packaged with spike proteins from the WT SARS-CoV-2 and  
276 the SARS-CoV-2 variants were produced according to a published protocol with  
277 minor modifications(22). Briefly, Vero-E6 cells were transfected with plasmids  
278 expressing different S proteins through the Lipofectamine 2000 (Biosharp, China).  
279 After 24 hrs, the transfected cells were inoculated with VSV-dG-fLuc ( $1 \times 10^6$   
280 TCID<sub>50</sub>/ml) diluted in DMEM for 5 hrs at 37°C and then replenished with growth  
281 medium (DMEM with 10 % FBS) containing anti-VSV-G monoclonal antibody  
282 (I1-hybridoma, cultured supernatant, 1:20). 24 hrs later, the SARS-CoV-2  
283 pseudovirus-containing supernatant was harvested and clarified at 3000 r.p.m for 10  
284 min, aliquoted, and frozen at -80°C for storage. The 50 % tissue culture infectious  
285 dose (TCID<sub>50</sub>) of pseudovirus was determined by a serial-dilution based infection  
286 assay on BHK-21-hACE2 cells and calculated according to the Reed-Muench  
287 method(22, 23).

288

#### 289 **SARS-CoV-2 pseudovirus neutralization assay**

290 The SARS-CoV-2 pseudoviruses were incubated with serial-diluted sera at room  
291 temperature for 30 mins in 96-well white flat-bottom culture plates and then mixed  
292 with trypsinized BHK-21-hACE2 cells with the density of  $2 \times 10^4$ /well. After 16 hrs,  
293 the medium of the infected cells was removed, and the cells were lysed with  $1 \times$   
294 Bright-Glo Luciferase Assay reagent (Promega) for chemiluminescence detection

295 with a SpectraMax iD3 Multi-well Luminometer (Molecular devices). The 50 %  
296 neutralization dilution titer (NT50) was calculated by GraphPad Prism 7 software  
297 with nonlinear regression curve fitting (normalized response, variable slope).

298

### 299 **Authentic SARS-CoV-2 neutralization assay**

300 The SARS-CoV-2 WT strain (IVCAS 6.7512) and B.1.351 strain (NPRC  
301 2.062100001)(24) were provided by the National Virus Resource, Wuhan Institute of  
302 Virology, Chinese Academy of Sciences, the SARS-CoV-2 B.1.1.7 strain (240108)  
303 was provided by HUBEI PROVINCIAL CENTR FOR DISEASE CONTROL AND  
304 PREVENTION. All SARS-CoV-2 authentic virus related experiments (S01321010A)  
305 were approved by the Biosafety Committee Level 3 (ABSL-3) of Wuhan University,  
306 Wuhan Institute of Virology and HUBEI PROVINCIAL CENTR FOR DISEASE  
307 CONTROL AND PREVENTION. In brief, sera were serially diluted in culture  
308 medium and mixed with 200 TCID<sub>50</sub> SARS-CoV-2 for 30 mins at room temperature.  
309 The mixture was then added to Vero E6 cells in 96-well plates and incubated for  
310 24 hrs, and the cells were fixed with 4 % paraformaldehyde in PBS at room  
311 temperature for 1 h, permeabilized with 0.2 % Triton X-100 for 10 mins, and then  
312 blocked with 1 % BSA/PBS at 37 °C for 1 h. Cells were subsequently incubated with  
313 a mouse monoclonal antibody targeting SARS-CoV/SARS-CoV-2 Nucleocapsid  
314 (40143-MM05, Sino Biological) at 1:500 dilution at 37 °C for 1 h, and then incubated  
315 with 2 µg/ml of Alexa Fluor 594-conjugated goat anti-mouse IgG antibody (A-11032,  
316 Thermo Fisher Scientific) at 37 °C for 1 h. The nucleus was stained with Hoechst

317 33342. Images were acquired with an inverted fluorescence microscope (DMi8,  
318 Leica).

### 319 **Statistical analysis**

320 Data are presented as mean values with s.e.m. or s.d.. All statistical analyses  
321 were done using GraphPad Prism 7. Differences between two independent samples  
322 were evaluated by two-tailed Mann–Whitney U-tests, and  $P < 0.05$  is considered  
323 statistically significant. Differences between two related samples were evaluated by  
324 paired two-tailed t-tests.

### 325 **Data availability**

326 All data are available in the manuscript or extended data.

327

### 328 **Acknowledgements**

329 This study was supported by grants from the National Science and Technology  
330 Major Project (2018YFA0900801), China NSFC projects (32041007 and 32070160),  
331 Fundamental Research Funds for the Central Universities (2042021kf0220 and  
332 2042020kf0024), the Advanced Customer Cultivation Project of Wuhan National  
333 Biosafety Laboratory (2021ACCP-MS10) and Special Fund for COVID-19 Research  
334 of Wuhan University. We are grateful to Beijing Taikang Yicai Foundation for their  
335 great support to this work.

336

### 337 **Author contributions**

338 K.L., Y.C., H.Y. and K.C. conceptualized the study design; F.H.M., F.X.Z., X.Y.C.,

339 B.H., J.Q.X and Y.Z.J. collected samples; Q.Y.L., Q.X., F.H.M., C.B.M., Z.Z., X.Y.C.,  
340 M.G., X.W., Y.H.F., S.S. and C.W.K. did the laboratory tests; Q.Y.L., Q.X., F.H.M.,  
341 Y.L.L., F.L., L.Z., K.X., C.W.K., F.D., H.Y. and Y.C. analysed the data; Q.Y.L., Q.X.,  
342 F.H.M., H.Y., Y.C. and K.L. interpreted the results; Q.Y.L., Q.X., F.H.M., H.Y. and  
343 Y.C. wrote the initial drafts of the manuscript; Q.Y.L., K.C., H.Y., Y.C. and K.L.  
344 revised the manuscript; Y.L.L., F.L., L.Z., K.X., C.W.K., J.Q.X., Y.Z.J. and F.D.  
345 commented on the manuscript. All authors read and approved the final manuscript.

346

#### 347 **Competing interests**

348 The authors declare no competing interests.

349

#### 350 **Additional information**

351 Supplementary information which includes Extended data figures and tables are  
352 available for this paper.

353

#### 354 **Reference:**

- 355 1. L. Ni, F. Ye, M. L. Cheng, Y. Feng, Y. Q. Deng, H. Zhao, P. Wei, J. Ge, M. Gou, X. Li, L. Sun, T. Cao,  
356 P. Wang, C. Zhou, R. Zhang, P. Liang, H. Guo, X. Wang, C. F. Qin, F. Chen, C. Dong, Detection of  
357 SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals.  
358 *Immunity* **52**, 971-977 e973 (2020); published online EpubJun 16  
359 (10.1016/j.immuni.2020.04.023).
- 360 2. J. A. Juno, H. X. Tan, W. S. Lee, A. Reynaldi, H. G. Kelly, K. Wragg, R. Esterbauer, H. E. Kent, C. J.  
361 Batten, F. L. Mordant, N. A. Gherardin, P. Pymm, M. H. Dietrich, N. E. Scott, W. H. Tham, D. I.  
362 Godfrey, K. Subbarao, M. P. Davenport, S. J. Kent, A. K. Wheatley, Humoral and circulating  
363 follicular helper T cell responses in recovered patients with COVID-19. *Nature medicine* **26**,  
364 1428-1434 (2020); published online EpubSep (10.1038/s41591-020-0995-0).
- 365 3. P. Zhou, X. L. Yang, X. G. Wang, B. Hu, L. Zhang, W. Zhang, H. R. Si, Y. Zhu, B. Li, C. L. Huang, H.  
366 D. Chen, J. Chen, Y. Luo, H. Guo, R. D. Jiang, M. Q. Liu, Y. Chen, X. R. Shen, X. Wang, X. S. Zheng,

- 367 K. Zhao, Q. J. Chen, F. Deng, L. L. Liu, B. Yan, F. X. Zhan, Y. Y. Wang, G. F. Xiao, Z. L. Shi, A  
368 pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* **579**,  
369 270-273 (2020); published online EpubMar (10.1038/s41586-020-2012-7).
- 370 4. N. D. Grubaugh, E. B. Hodcroft, J. R. Fauver, A. L. Phelan, M. Cevik, Public health actions to  
371 control new SARS-CoV-2 variants. *Cell* **184**, 1127-1132 (2021); published online EpubMar 4  
372 (10.1016/j.cell.2021.01.044).
- 373 5. Investigation of novel SARS-CoV-2 variant: Variant of Concern 202012/01. Technical Briefing 5.  
374 *Public Health England*, (2020).
- 375 6. H. Tegally, E. Wilkinson, M. Giovanetti, A. Iranzadeh, V. Fonseca, J. Giandhari, D. Doolabh, S.  
376 Pillay, E. J. San, N. Msomi, K. Mlisana, A. von Gottberg, S. Walaza, M. Allam, A. Ismail, T.  
377 Mohale, A. J. Glass, S. Engelbrecht, G. Van Zyl, W. Preiser, F. Petruccione, A. Sigal, D. Hardie, G.  
378 Marais, M. Hsiao, S. Korsman, M.-A. Davies, L. Tyers, I. Mudau, D. York, C. Maslo, D. Goedhals,  
379 S. Abrahams, O. Laguda-Akingba, A. Alisoltani-Dehkordi, A. Godzik, C. K. Wibmer, B. T. Sewell,  
380 J. Lourenço, L. C. J. Alcantara, S. L. K. Pond, S. Weaver, D. Martin, R. J. Lessells, J. N. Bhiman, C.  
381 Williamson, T. de Oliveira, Emergence and rapid spread of a new severe acute respiratory  
382 syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South  
383 Africa. *medRxiv*, 2020.2012.2021.20248640 (2020)10.1101/2020.12.21.20248640).
- 384 7. N. R. Faria, I. M. Claro, D. Candido, L. A. M. Franco, P. S. Andrade, Genomic characterisation of  
385 an emergent SARS-CoV-2 lineage in Manaus: preliminary findings. (2021).
- 386 8. E. A. Ozer, L. M. Simons, O. M. Adewumi, A. A. Fowotade, E. C. Omoruyi, J. A. Adeniji, T. J.  
387 Dean, B. O. Taiwo, J. F. Hultquist, R. Lorenzo-Redondo, High prevalence of SARS-CoV-2 B.1.1.7  
388 (UK variant) and the novel B.1.5.2.5 lineage in Oyo State, Nigeria. *medRxiv*, (2021);  
389 published online EpubApr 17 (10.1101/2021.04.09.21255206).
- 390 9. P. D. Yadav, D. A. Nyayanit, R. R. Sahay, P. Sarkale, J. Pethani, S. Patil, S. Baradkar, V. Potdar, D. Y.  
391 Patil, Isolation and characterization of the new SARS-CoV-2 variant in travellers from the  
392 United Kingdom to India: VUI-202012/01 of the B.1.1.7 lineage. *Journal of travel medicine* **28**,  
393 (2021); published online EpubFeb 23 (10.1093/jtm/taab009).
- 394 10. J. S. Turner, W. Kim, E. Kalaidina, C. W. Goss, A. M. Rauseo, A. J. Schmitz, L. Hansen, A. Haile,  
395 M. K. Klebert, I. Pusic, J. A. O'Halloran, R. M. Presti, A. H. Ellebedy, SARS-CoV-2 infection  
396 induces long-lived bone marrow plasma cells in humans. *Nature*, (2021); published online  
397 EpubMay 24 (10.1038/s41586-021-03647-4).
- 398 11. Z. He, L. Ren, J. Yang, L. Guo, L. Feng, C. Ma, X. Wang, Z. Leng, X. Tong, W. Zhou, G. Wang, T.  
399 Zhang, Y. Guo, C. Wu, Q. Wang, M. Liu, C. Wang, M. Jia, X. Hu, Y. Wang, X. Zhang, R. Hu, J.  
400 Zhong, J. Yang, J. Dai, L. Chen, X. Zhou, J. Wang, W. Yang, C. Wang, Seroprevalence and  
401 humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal,  
402 population-level, cross-sectional study. *Lancet* **397**, 1075-1084 (2021); published online  
403 EpubMar 20 (10.1016/S0140-6736(21)00238-5).
- 404 12. P. Wang, M. S. Nair, L. Liu, S. Iketani, Y. Luo, Y. Guo, M. Wang, J. Yu, B. Zhang, P. D. Kwong, B. S.  
405 Graham, J. R. Mascola, J. Y. Chang, M. T. Yin, M. Sobieszczyk, C. A. Kyratsous, L. Shapiro, Z.  
406 Sheng, Y. Huang, D. D. Ho, Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.  
407 *Nature* **593**, 130-135 (2021); published online EpubMay (10.1038/s41586-021-03398-2).
- 408 13. M. Hoffmann, P. Arora, R. Gross, A. Seidel, B. F. Hornich, A. S. Hahn, N. Kruger, L. Graichen, H.  
409 Hofmann-Winkler, A. Kempf, M. S. Winkler, S. Schulz, H. M. Jack, B. Jahrsdorfer, H.  
410 Schrezenmeier, M. Muller, A. Kleger, J. Munch, S. Pohlmann, SARS-CoV-2 variants B.1.351 and

- 411 P.1 escape from neutralizing antibodies. *Cell* **184**, 2384-2393 e2312 (2021); published online  
412 EpubApr 29 (10.1016/j.cell.2021.03.036).
- 413 14. S. Cao, Y. Gan, C. Wang, M. Bachmann, S. Wei, J. Gong, Y. Huang, T. Wang, L. Li, K. Lu, H. Jiang,  
414 Y. Gong, H. Xu, X. Shen, Q. Tian, C. Lv, F. Song, X. Yin, Z. Lu, Post-lockdown SARS-CoV-2 nucleic  
415 acid screening in nearly ten million residents of Wuhan, China. *Nature communications* **11**,  
416 5917 (2020); published online EpubNov 20 (10.1038/s41467-020-19802-w).
- 417 15. V. Tchesnokova, H. Kulakesara, L. Larson, V. Bowers, E. Rechkina, D. Kisiela, Y. Sledneva, D.  
418 Choudhury, I. Maslova, K. Deng, K. Kutumbaka, H. Geng, C. Fowler, D. Greene, J. Ralston, M.  
419 Samadpour, E. Sokurenko, Acquisition of the L452R mutation in the ACE2-binding interface of  
420 Spike protein triggers recent massive expansion of SARS-Cov-2 variants. *bioRxiv : the preprint*  
421 *server for biology*, (2021); published online EpubMar 11 (10.1101/2021.02.22.432189).
- 422 16. D. Zhou, W. Dejnirattisai, P. Supasa, C. Liu, A. J. Mentzer, H. M. Ginn, Y. Zhao, H. M. E.  
423 Duyvesteyn, A. Tuekprakhon, R. Nutalai, B. Wang, G. C. Paesen, C. Lopez-Camacho, J.  
424 Slon-Campos, B. Hallis, N. Coombes, K. Bewley, S. Charlton, T. S. Walter, D. Skelly, S. F. Lumley,  
425 C. Dold, R. Levin, T. Dong, A. J. Pollard, J. C. Knight, D. Crook, T. Lambe, E. Clutterbuck, S. Bibi,  
426 A. Flaxman, M. Bittaye, S. Belij-Rammerstorfer, S. Gilbert, W. James, M. W. Carroll, P.  
427 Klenerman, E. Barnes, S. J. Dunachie, E. E. Fry, J. Mongkolsapaya, J. Ren, D. I. Stuart, G. R.  
428 Screaton, Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and  
429 vaccine-induced sera. *Cell* **184**, 2348-2361 e2346 (2021); published online EpubApr 29  
430 (10.1016/j.cell.2021.02.037).
- 431 17. A. W. D. Edridge, J. Kaczorowska, A. C. R. Hoste, M. Bakker, M. Klein, K. Loens, M. F. Jebbink, A.  
432 Matser, C. M. Kinsella, P. Rueda, M. Ieven, H. Goossens, M. Prins, P. Sastre, M. Deijs, L. van  
433 der Hoek, Seasonal coronavirus protective immunity is short-lasting. *Nature medicine* **26**,  
434 1691-1693 (2020); published online EpubNov (10.1038/s41591-020-1083-1).
- 435 18. G. L. Wang, Z. Y. Wang, L. J. Duan, Q. C. Meng, M. D. Jiang, J. Cao, L. Yao, K. L. Zhu, W. C. Cao,  
436 M. J. Ma, Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization. *The New*  
437 *England journal of medicine*, (2021); published online EpubApr 6 (10.1056/NEJMc2103022).
- 438 19. P. Y. Shi, X. Xie, J. Zou, C. Fontes-Garfias, H. Xia, K. Swanson, M. Cutler, D. Cooper, V.  
439 Menachery, S. Weaver, P. Dormitzer, Neutralization of N501Y mutant SARS-CoV-2 by  
440 BNT162b2 vaccine-elicited sera. *Research square*, (2021); published online EpubJan 13  
441 (10.21203/rs.3.rs-143532/v1).
- 442 20. X. Xie, Y. Liu, J. Liu, X. Zhang, J. Zou, C. R. Fontes-Garfias, H. Xia, K. A. Swanson, M. Cutler, D.  
443 Cooper, V. D. Menachery, S. C. Weaver, P. R. Dormitzer, P. Y. Shi, Neutralization of SARS-CoV-2  
444 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. *Nature*  
445 *medicine* **27**, 620-621 (2021); published online EpubApr (10.1038/s41591-021-01270-4).
- 446 21. C. Schwegmann-Wessels, J. Glende, X. Ren, X. Qu, H. Deng, L. Enjuanes, G. Herrler,  
447 Comparison of vesicular stomatitis virus pseudotyped with the S proteins from a porcine and  
448 a human coronavirus. *The Journal of general virology* **90**, 1724-1729 (2009); published online  
449 EpubJul (10.1099/vir.0.009704-0).
- 450 22. J. Nie, Q. Li, J. Wu, C. Zhao, H. Hao, H. Liu, L. Zhang, L. Nie, H. Qin, M. Wang, Q. Lu, X. Li, Q.  
451 Sun, J. Liu, C. Fan, W. Huang, M. Xu, Y. Wang, Quantification of SARS-CoV-2 neutralizing  
452 antibody by a pseudotyped virus-based assay. *Nature protocols* **15**, 3699-3715 (2020);  
453 published online EpubNov (10.1038/s41596-020-0394-5).
- 454 23. M. Matumoto, A note on some points of calculation method of LD50 by Reed and Muench.

455 *The Japanese journal of experimental medicine* **20**, 175-179 (1949); published online EpubSep  
456 (  
457 24. C. Fengjuan, L. Bosheng, H. Peter, S. Yang, X. Wenbo, L. Nankun, L. Chunliang, K. Changwen, A  
458 Case of New Variant COVID-19 First Emerging in South Africa Detected in Airplane Pilot —  
459 Guangdong Province, China, January 6, 2021. *China CDC Weekly* **3**, 28-29  
460 (2021)10.46234/ccdcw2021.007).

461

462

### 463 **Figure legend**

464

465 **Fig. 1: The anti-RBD IgG level and neutralizing activity of sera from COVID-19**  
466 **patients in Wuhan one-year after recovery.**

467 **a-e**, Results of ELISA measuring the 248 convalescent COVID-19 patients' sera reactivity to  
468 SARS-CoV-2-RBD. The anti-RBD IgG level of the indicated groups (**a**, **c**). The competitive  
469 ability of ACE2 to RBD-binding of the indicated groups (**b**, **d**). **Comparison of the anti-RBD IgG**  
470 **and the competitive ability of ACE2 to RBD-binding in patients with different age (e).** **f**, The  
471 neutralizing activity (WT-D614G) of the sera from convalescents with different severity was  
472 tested with the indicated dilution folds. Mean  $\pm$  s.d. are shown in **a-d**. Mean  $\pm$  s.e.m are shown in **e**.  
473 Statistical significance was determined using two-tailed Mann-Whitney U-tests, and no  
474 significant difference was found ( $P > 0.05$ ). The horizontal dotted lines on **a** and **c** indicate the  
475 cut-off value (0.45, three times of t the mean OD450 value of uninfected people's sera).

476

477 **Fig. 2: The neutralizing activity of the convalescents' sera to SARS-CoV-2 variants.**

478 **a**, The amino acid alterations in the S protein of SARS-CoV-2 variants tested in this study. **b**, The  
479 neutralizing activity of convalescents' sera at 100-fold dilution against pseudoviruses bearing S  
480 proteins from the indicated variants with WT-D614G as a control. **c-e**, Paired analysis of NT<sub>50</sub>  
481 values of convalescents' sera or RBD vaccinated mice sera against WT-D614G and variants.  
482 Serum group 1: relatively resistant (**c**). Serum group 2: sensitive (**d**). RBD-vaccinated mice sera (**e**).  
483 The serum group 1 and 2 were selected according to their tolerance to mutations in B.1.351.  
484 Statistical significance was determined using paired two-tailed t-tests.  $P$  values and mean fold  
485 changes in NT<sub>50</sub> values compared with WT-D614G are indicated. **f**, The neutralizing activity of  
486 convalescents' sera at 100-fold dilution against pseudoviruses bearing different S with indicated  
487 mutations. •, the relatively resistant serum sample. ★, the sensitive serum sample.

488

489 **Fig. 3: The neutralizing activity of the convalescents' sera to authentic SARS-CoV-2 viruses.**

490 **a**, The neutralizing activity of 30 representative sera against authentic SARS-CoV-2 WT strain at  
491 20-fold and 100-fold dilution. The sera were grouped based on their neutralizing activity to  
492 WT-D614G pseudoviruses. **b-c**, The neutralizing activity of the selected sera (relatively resistant  
493 or sensitive against B.1.351 pseudovirus) against the indicated authentic SARS-CoV-2 viruses.  
494 SARS-CoV-2 N protein (red) in the infected cells was detected through immunofluorescence  
495 assay at 24 h post-infection. The nucleus was stained blue. Scale bar, 200  $\mu$ m. The serum sample  
496 number were indicated above the pictures.

497

498 **Extended data Fig. 1: The neutralizing activity of the convalescents' sera to WT-D614G and**  
499 **variants for NT<sub>50</sub> determination.**


500 Convalescents' sera were serially diluted and then were inoculated with  $3 \times 10^5$  TCID<sub>50</sub>  
501 pseudoviruses as indicated for 30 min at room temperature. BHK-21-hACE2 cells were infected  
502 by this mixture, followed by a chemiluminescence detection after 16 hrs. Mean  $\pm$  s.d. (n=2) are  
503 shown. The NT<sub>50</sub> was calculated by GraphPad Prism 7 software with nonlinear regression curve  
504 fitting (normalized response, variable slope). The horizontal dotted lines on each graph indicate  
505 50 % and 0 % neutralization.

506

507 **Extended data Table 1: The clinical records and sera reactivity to SARS-CoV-2 of the**  
508 **convalescents in this study.**

509

510 Fig. 1



511


512

513 Fig. 2


A

	NTD											RBD											CTD										
	L18	T20	P26	Q52	A67	H69 & V70	D80	D138	Y144	R190	D215	L242-244	K417	E484	N501	A570	D614	H655	P681	A701	T716	F888	S982	T1027	D1118	V1176							
WT-D614G																	G																
B.1.1.7 (the United Kingdom)						del			del							Y	D	G		H		I		A		H							
P.1 (Brazil)	F	N	S					Y	S				T	K	Y		G	Y						I		F							
B.1.525 (Nigeria)				R	V	del		del						K			G	Y				L											
B.1.351(South Africa)						A					G	del	N	K	Y		G			V													


B




C




D



E



F



514

515

516 **Fig. 3**

